Atrial Fibrillation - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 103 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Atrial Fibrillation - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Atrial Fibrillation - Pipeline Review, H1 2015', provides an overview of the Atrial Fibrillation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Atrial Fibrillation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Atrial Fibrillation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atrial Fibrillation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Atrial Fibrillation Overview 9
Therapeutics Development 10
Pipeline Products for Atrial Fibrillation - Overview 10
Pipeline Products for Atrial Fibrillation - Comparative Analysis 11
Atrial Fibrillation - Therapeutics under Development by Companies 12
Atrial Fibrillation - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Atrial Fibrillation - Products under Development by Companies 17
Atrial Fibrillation - Companies Involved in Therapeutics Development 19
ARCA biopharma, Inc. 19
Armetheon, Inc. 20
AstraZeneca PLC 21
Bristol-Myers Squibb Company 22
Cardiome Pharma Corp 23
Daiichi Sankyo Company, Limited 24
Gilead Sciences, Inc. 25
Isis Pharmaceuticals, Inc. 26
Laboratoires Pierre Fabre SA 27
Nissan Chemical Industries, Ltd. 28
Nyken BV 29
Otsuka Holdings Co., Ltd. 30
Regado Biosciences, Inc. 31
Serodus ASA 32
Xention Limited 33
Atrial Fibrillation - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
(ranolazine + dronedarone) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Aptamers for Cardiovascular Diseases - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BMS-919373 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
bucindolol hydrochloride - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
budiodarone - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drug For Atrial Fibrillation - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
edoxaban tosylate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
F-373280 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
GsMTx-4 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ISIS-CRPRx - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NIP-151 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
NYK-1112 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
OMT-33 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
OPC-108459 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ranolazine ER - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SER-102 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecule to Block IKACh for Atrial Fibrillation - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules to Activate Heat Shock Protein 70 (Hsp70) for Post-Operative Atrial Fibrillation - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
vanoxerine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
vernakalant hydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
XEN-D0101 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
XEN-D0103 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
XEN-R0702 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Atrial Fibrillation - Recent Pipeline Updates 78
Atrial Fibrillation - Dormant Projects 90
Atrial Fibrillation - Discontinued Products 94
Atrial Fibrillation - Product Development Milestones 95
Featured News & Press Releases 95
Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 95
Nov 07, 2014: Cardiome Announces Positive Results from the BRINAVESS Asia-Pacific Phase 3 Clinical Trial 95
Nov 07, 2014: Cardiome Submits BRINAVESS Reimbursement Dossier to Italian Authorities to Support Market Access 96
Oct 31, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA� (edoxaban) for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 96
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 97
Sep 26, 2014: Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan 98
Sep 02, 2014: Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes 98
Sep 01, 2014: Xention commences first phase 2 study of XEN-D0103 in atrial fibrillation 100
Aug 25, 2014: Cardiome Enters Commercialization Agreement With Eurolab Especialidades Medicinales For BRINAVESS In Argentina 101
Aug 06, 2014: Cardiome Submits Brinavess Dossier To French Authorities To Support Market Access 101
Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 103
Disclaimer 103

List of Tables
Number of Products under Development for Atrial Fibrillation, H1 2015 10
Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Atrial Fibrillation - Pipeline by ARCA biopharma, Inc., H1 2015 19
Atrial Fibrillation - Pipeline by Armetheon, Inc., H1 2015 20
Atrial Fibrillation - Pipeline by AstraZeneca PLC, H1 2015 21
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H1 2015 22
Atrial Fibrillation - Pipeline by Cardiome Pharma Corp, H1 2015 23
Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 24
Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H1 2015 25
Atrial Fibrillation - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 26
Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H1 2015 27
Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H1 2015 28
Atrial Fibrillation - Pipeline by Nyken BV, H1 2015 29
Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 30
Atrial Fibrillation - Pipeline by Regado Biosciences, Inc., H1 2015 31
Atrial Fibrillation - Pipeline by Serodus ASA, H1 2015 32
Atrial Fibrillation - Pipeline by Xention Limited, H1 2015 33
Assessment by Monotherapy Products, H1 2015 34
Assessment by Combination Products, H1 2015 35
Number of Products by Stage and Target, H1 2015 37
Number of Products by Stage and Mechanism of Action, H1 2015 39
Number of Products by Stage and Route of Administration, H1 2015 41
Number of Products by Stage and Molecule Type, H1 2015 43
Atrial Fibrillation Therapeutics - Recent Pipeline Updates, H1 2015 78
Atrial Fibrillation - Dormant Projects, H1 2015 90
Atrial Fibrillation - Dormant Projects (Contd..1), H1 2015 91
Atrial Fibrillation - Dormant Projects (Contd..2), H1 2015 92
Atrial Fibrillation - Dormant Projects (Contd..3), H1 2015 93
Atrial Fibrillation - Discontinued Products, H1 2015 94